Abstract:Psychedelics changes in perception through serotonin receptor agonism. Effects on the 5HT2A receptor; neuroplasticity and transcriptomic regulation, as well as specific changes in neural correlates of brain networks. Psychedelic‐assisted therapy in disorders such as depression, anxiety and substance use disorders constitutes a strong research area, thus evaluating the clinical use is highly essential (this figure was created with BioRender.com). Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for thousands of years. Classical psychedelics from N,N′‐dimethyltryptamine, psilocybin, mescaline and various lysergamides cause specific alterations in perception, emotion and cognition by acting through serotonin 5‐HT2A receptor activation. Lysergic acid diethylamide, the first famous breakthrough in the field, was discovered by chance by Albert Hoffman in the Zurich Sandoz laboratory in 1943, and studies on its psychoactive effects began to take place in the literature. Studies in this area were blocked after the legislation controlling the use and research of psychedelic drugs came into force in 1967, but since the 1990s, it has started to be a matter of scientific curiosity again by various research groups. In particular, with the crucial reports of psychotherapy‐assisted psilocybin applications for life‐threatening cancer‐related anxiety and depression, a new avenues have been opened in the treatment of psychiatric diseases such as treatment‐resistant depression and substance addictions. An increasing number of studies show that psychedelics have a very promising potential in the treatment of neuropsychiatric diseases where the desired efficiency cannot be achieved with conventional treatment methods. In this context, we discuss psychedelic therapy, encompassing its historical development, therapeutic applications and potential treatment effects—especially in depression, trauma disorders and substance use disorders—within the framework of ethical considerations.

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?

[Therapeutic applications of classical serotonergic psyche-delics: neurobiological mechanisms and neural networks]

The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

Psychedelics and Neural Plasticity: Therapeutic Implications

Psychedelic therapy in depression and substance use disorders

Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties

Psychedelics and Other Psychoplastogens for Treating Mental Illness

The phenomenology of psychedelic temporality: current knowledge, open questions, and clinical applications

Unifying Theories of Psychedelic Drug Effects

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

Psilocybin, moralization and psychotherapy: a coping review and a case report

Psychedelic research at a crossroads

The economics of psychedelic-assisted therapies: A research agenda

Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action

Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review

Neuroplasticity and Psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies